Tags

Type your tag names separated by a space and hit enter

Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases.
Ann N Y Acad Sci. 2008 Dec; 1147:112-21.AN

Abstract

Mitochondrial impairment and oxidative damage are intimately involved in the pathogenesis of neurodegenerative diseases. Which is the initiating event is probably irrelevant because each can set into motion a self-sustaining and amplifying feed-forward cycle between reactive oxygen species (ROS) generation and mitochondrial impairment. Recent approaches to the development of neuroprotective agents have therefore targeted mitochondria protection and/or reduction of oxidative stress. There are several hurdles in the quest for neuroprotective drugs. The difficulties include penetration of the blood-brain barrier and delivery of drugs to mitochondria. Here we describe a novel class of mitochondria-targeted peptides that can promote mitochondrial function, reduce mitochondrial ROS generation, inhibit mitochondrial permeability transition, and prevent apoptosis and necrosis. These peptides can readily penetrate the blood-brain barrier and have demonstrated efficacy in animal models of Parkinson's disease and amyotrophic lateral sclerosis.

Authors+Show Affiliations

Department of Pharmacology, Joan and Sanford I Weill Medical College of Cornell University, New York, NY 10021, USA. hhszeto@med.cornell.edu

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

19076436

Citation

Szeto, Hazel H.. "Development of Mitochondria-targeted Aromatic-cationic Peptides for Neurodegenerative Diseases." Annals of the New York Academy of Sciences, vol. 1147, 2008, pp. 112-21.
Szeto HH. Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases. Ann N Y Acad Sci. 2008;1147:112-21.
Szeto, H. H. (2008). Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases. Annals of the New York Academy of Sciences, 1147, 112-21. https://doi.org/10.1196/annals.1427.013
Szeto HH. Development of Mitochondria-targeted Aromatic-cationic Peptides for Neurodegenerative Diseases. Ann N Y Acad Sci. 2008;1147:112-21. PubMed PMID: 19076436.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases. A1 - Szeto,Hazel H, PY - 2008/12/17/entrez PY - 2008/12/17/pubmed PY - 2009/1/8/medline SP - 112 EP - 21 JF - Annals of the New York Academy of Sciences JO - Ann N Y Acad Sci VL - 1147 N2 - Mitochondrial impairment and oxidative damage are intimately involved in the pathogenesis of neurodegenerative diseases. Which is the initiating event is probably irrelevant because each can set into motion a self-sustaining and amplifying feed-forward cycle between reactive oxygen species (ROS) generation and mitochondrial impairment. Recent approaches to the development of neuroprotective agents have therefore targeted mitochondria protection and/or reduction of oxidative stress. There are several hurdles in the quest for neuroprotective drugs. The difficulties include penetration of the blood-brain barrier and delivery of drugs to mitochondria. Here we describe a novel class of mitochondria-targeted peptides that can promote mitochondrial function, reduce mitochondrial ROS generation, inhibit mitochondrial permeability transition, and prevent apoptosis and necrosis. These peptides can readily penetrate the blood-brain barrier and have demonstrated efficacy in animal models of Parkinson's disease and amyotrophic lateral sclerosis. SN - 1749-6632 UR - https://www.unboundmedicine.com/medline/citation/19076436/Development_of_mitochondria_targeted_aromatic_cationic_peptides_for_neurodegenerative_diseases_ L2 - https://doi.org/10.1196/annals.1427.013 DB - PRIME DP - Unbound Medicine ER -